Document text
Principal Investigator: Steffen Mueller
Organization: CODAGENIX, INC.
Fiscal Year: 2020
Award: $1,716,496
Funding agency: National Institute of Allergy and Infectious Diseases
There is a clear unmet need for a vaccine against the ongoing epidemic of coronavirus disease 2019 (COVID19) caused by SARS-CoV-2. SARS-CoV-2 was initially detected in the Hubei Province of China late in 2019.
SARS-CoV-2 is highly contagious (R0 of 1.4-3.9, greater than seasonal influenza), and presents with fever,
cough, fatigue, and shortness of breath. Older patients and those with underlying health conditions may be at
a higher risk of severe illness, with most reported cases having occurred in adults (median 59 years of age).
There are no vaccines or other medical countermeasures available against SARS-CoV-2. This submission is an
Administrative Supplement to 1R44AI131756-01 in response to NOT-AI-20-030, where we describe our
approach to pre-clinical testing of our SARS-CoV-2 vaccine candidates. In the parent grant application,
Codagenix is developing a safe and effective RSV vaccine based on Codagenix’s algorithm-based platform for
rapid generation of vaccines. Together, the respiratory illnesses caused by RSV and SARS-CoV-2 present major
public health threats. In this administrative supplement, we seek to apply our “synthetic attenuated virus
engineering" (SAVE) platform to design and develop a live-attenuated vaccine (LAV) against SARS-CoV-2.
SAVE relies on large-scale DNA synthesis and rational re-design of a target virus to construct a vaccine that is
“deoptimized” for protein expression in human cells. The SAVE platform has been used to generate vaccines
against multiple viruses including influenza, Zika, dengue, RSV, and others. One SAVE-based vaccine is
currently in the clinic in Phase I trials under a US IND, and another entering clinical trials in Q1-20,
demonstrating the proof of principle behind SAVE. We already initiated the SARS-CoV-2 vaccine development
in a real-time response to the ongoing epidemic of SARS-CoV-2. Using our SAVE platform, we designed six
vaccine candidates that are deoptimized to varying extents across the RdRp and Spike genes, along with a
synthetic wt SARS-CoV-2. These genomes were synthesized de novo, assembled, sequenced, and are now
ready for recovery following transfection in cell culture. Candidate vaccine viruses will be recovered under
BSL-3 containment, passaged, deep sequenced, and screened for attenuation, immunogenicity and efficacy in a
primate model. We expect at least one, but likely 4 viruses will be recovered from transfection. Three of the
best-growing viruses (growing to >104 TCID50/ml) will be tested for safety, immunogenicity and efficacy in
African green monkeys, previously used for SARS studies. Following the completion of the work described
here, using non-grant funding, two of the viruses that perform best in primate studies will be put through GLP
toxicity screening, GMP manufacturing and a Phase I clinical trials.
Terms: <2019 novel coronavirus><2019-nCoV><21+ years old><Administrative Supplement><Adult><Adult Human><African Green Monkey><Age-Years><Algorithms><Antigens><Applications Grants><Attenuated><Attenuated Live Virus Vaccine><Attenuated Vaccines><COVID-19><COVID-19 epidemic><COVID-19 pandemic><COVID19><COVID19 epidemic><COVID19 pandemic><Case Study><Causality><Cell Body><Cell Culture Techniques><Cells><Cessation of life><China><Chlorocebus aethiops><Chlorocebus sabaeus><Clinic><Clinical><Clinical Trials><Codon><Codon Nucleotides><Complementary DNA><Containment><Coughing><Country><Cyclic GMP><DNA Replication><DNA Synthesis><DNA biosynthesis><Death><Dengue><Development><Disadvantaged><Dose><Early-Stage Clinical Trials><Engineering><Ensure><Epidemic><Equilibrium><Etiology><Fatigue><Fever><Funding><Future><Gene Transcription><Generations><Genes><Genetic Transcription><Genome><Genomics><Genotype><Goals><Grant><Grant Proposals><Green Monkey><Grippe><Guanosine Cyclic Monophosphate><Health><Human><Immunity><In Vitro><Influenza><Influenza Vaccines><Lack of Energy><Legal patent><Length><Live-attenuated Vaccine><Mainland China><Measures><Modeling><Modern Man><NGS Method><NGS system><Non-Polyadenylated RNA><Patents><Patients><Persons><Phase><Phase 1 Clinical Trials><Phase I Clinical Trials><Phenotype><Phone><Preclinical Testing><Prevention><Primates><Primates Mammals><Production><Province><Public Health><Pyrexia><RNA><RNA Expression><RNA Gene Products><RSV Vaccines><Reaction Time><Recovery><Respiratory Infections><Respiratory Syncytial Virus Vaccines><Respiratory Tract Infections><Response RT><Response Time><Ribonucleic Acid><SARS><SARS Virus><SARS corona virus><SARS coronavirus><SARS coronavirus disease><SARS-Associated Coronavirus><SARS-CoV><SARS-CoV disease><SARS-CoV-2><SARS-CoV2><SARS-Related Coronavirus><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related coronavirus 2><Safety><Severe Acute Respiratory Syndrome><Severe Acute Respiratory Syndrome CoV disease><Severe Acute Respiratory Syndrome Virus><Severe Acute Respiratory Syndrome corona virus><Severe Acute Respiratory Syndrome coronavirus><Severe Acute Respiratory Syndrome coronavirus disease><Severe acute respiratory syndrome coronavirus 2><Shortness of Breath><Technology><Telephone><Testing><Therapeutic><Time><Toxic effect><Toxicities><Toxicology><Transcription><Transfection><Translating><Translations><Transmission><Vaccine Design><Vaccines><Vero Cells><Viral><Viral Genome><Viral Shedding><Virus><Virus Replication><Virus Shedding><Work><Wuhan coronavirus><ZIKA><adulthood><attenuation><balance><balance function><base><cDNA><cGMP><case report><causation><cell culture><clinical material><combat><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><coronavirus disease 2019><coronavirus disease 2019 epidemic><coronavirus disease 2019 pandemic><design><designing><develop a vaccine><development of a vaccine><developmental><disease causation><elderly patient><entire genome><febrile><febris><flu infection><flu vaccine><flu virus vaccine><full genome><genomic RNA><high risk><immunogen><immunogenicity><in vivo><in vivo evaluation><in vivo testing><influenza infection><influenza virus vaccine><live vaccine><manufacturing scale-up><medical countermeasure><neutralizing antibody><new approaches><next gen sequencing><next generation sequencing><nextgen sequencing><novel approaches><novel strategies><novel strategy><older patient><parent grant><phase 1 trial><phase I protocol><phase I trial><pre-clinical study><pre-clinical testing><preclinical study><prevent><preventing><protein expression><psychomotor reaction time><public health emergency><respiratory><response><safety testing><screening><seasonal flu><seasonal influenza><severe acute respiratory syndrome-CoV><transmission process><vaccine against flu><vaccine against influenza><vaccine candidate><vaccine development><vaccine formulation><viral multiplication><viral replication><virus genome><virus multiplication><whole genome>